Fabiana Perna: Honored to Share New Discoveries in Cancer Immunotherapy at AACR
Fabiana Perna/X

Fabiana Perna: Honored to Share New Discoveries in Cancer Immunotherapy at AACR

Fabiana Perna, Senior Member, Medical Director, Cell Therapy Facility at Moffitt Cancer Center, shared on X:

“I was honored and grateful to present my lab’s work on discovering the next generation of cancer immunotherapy targets as plenary speaker at the AACR conference in precision medicine in Gyeongjiu, Korea.

It was a real pleasure to spend time with an outstanding group of exceptionally smart and dedicated colleagues.

Learning from their discoveries on multiple types of cancer was mind blowing and so inspiring. Thank you to Dr. Keith Flaherty and the AACR for the invitation and the Korean Cancer Association (KCA) for the warm hospitality.”

Fabiana Perna: Honored to Share New Discoveries in Cancer Immunotherapy at AACR

The 8th AACR-KCA Joint Conference on Precision Medicine in Cancer took place from November 12–13, 2026, at the Hwabaek International Convention Center (HICO) in Gyeongju, South Korea. Co-organized by the American Association for Cancer Research (AACR) and the Korean Cancer Association (KCA), the event concluded recently, with recorded sessions becoming available for on-demand viewing. 

The conference focused on translating emerging molecular, computational, and therapeutic discoveries into personalized cancer care, bringing together clinicians, researchers, and industry experts to address tumor evolution, treatment resistance, and next-generation diagnostics.

Core Scientific Themes:

Across two days of plenary and educational sessions detailed in the AACR-KCA 2026 Program, discussions centered on several major areas:

  • AI and Computational Oncology: How artificial intelligence and spatial omics map tumor microenvironments, track tumor evolution, and guide clinical decision-making.
  • Liquid Biopsy and Diagnostics: Using non-invasive blood biomarkers to detect cancer earlier, monitor disease progression, and tailor targeted treatments. 
  • Next-Generation Therapeutics: Advances in surface-targeting modalities – such as antibody-drug conjugates (ADCs) – alongside applied chemistry for novel drug discovery.
  • Precision Immunotherapy and the Microbiome: Identifying and targeting immune-evasive tumors, as well as exploring how the microbiome influences cancer therapy responses.
  • Disease-Specific Focus Areas: Dedicated sessions examining precision approaches for gastric cancer (a major focus in East Asian oncology) and hematologic malignancies.

You can also read:

Fabiana Perna: Honored to Share New Discoveries in Cancer Immunotherapy at AACR